全文获取类型
收费全文 | 46767篇 |
免费 | 3345篇 |
国内免费 | 190篇 |
专业分类
耳鼻咽喉 | 375篇 |
儿科学 | 1508篇 |
妇产科学 | 1200篇 |
基础医学 | 6592篇 |
口腔科学 | 590篇 |
临床医学 | 5039篇 |
内科学 | 9743篇 |
皮肤病学 | 876篇 |
神经病学 | 5540篇 |
特种医学 | 1121篇 |
外科学 | 4157篇 |
综合类 | 390篇 |
一般理论 | 58篇 |
预防医学 | 5677篇 |
眼科学 | 617篇 |
药学 | 2989篇 |
中国医学 | 88篇 |
肿瘤学 | 3742篇 |
出版年
2024年 | 59篇 |
2023年 | 654篇 |
2022年 | 1088篇 |
2021年 | 2155篇 |
2020年 | 1302篇 |
2019年 | 1778篇 |
2018年 | 2037篇 |
2017年 | 1363篇 |
2016年 | 1516篇 |
2015年 | 1663篇 |
2014年 | 2027篇 |
2013年 | 2624篇 |
2012年 | 4197篇 |
2011年 | 4151篇 |
2010年 | 2103篇 |
2009年 | 1845篇 |
2008年 | 2947篇 |
2007年 | 2906篇 |
2006年 | 2775篇 |
2005年 | 2568篇 |
2004年 | 2278篇 |
2003年 | 2034篇 |
2002年 | 1733篇 |
2001年 | 193篇 |
2000年 | 144篇 |
1999年 | 211篇 |
1998年 | 348篇 |
1997年 | 263篇 |
1996年 | 212篇 |
1995年 | 175篇 |
1994年 | 125篇 |
1993年 | 117篇 |
1992年 | 69篇 |
1991年 | 66篇 |
1990年 | 58篇 |
1989年 | 57篇 |
1988年 | 51篇 |
1987年 | 37篇 |
1986年 | 38篇 |
1985年 | 34篇 |
1984年 | 46篇 |
1983年 | 44篇 |
1982年 | 33篇 |
1981年 | 41篇 |
1980年 | 28篇 |
1979年 | 17篇 |
1978年 | 13篇 |
1977年 | 20篇 |
1975年 | 9篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
Jennifer C. Sasaki Ashley Allemang Steven M. Bryce Laura Custer Kerry L. Dearfield Yasmin Dietz Azeddine Elhajouji Patricia A. Escobar Albert J. Fornace Jr Roland Froetschl Sheila Galloway Ulrike Hemmann Giel Hendriks Heng-Hong Li Mirjam Luijten Gladys Ouedraogo Lauren Peel Stefan Pfuhler Daniel J. Roberts Véronique Thybaud Jan van Benthem Carole L. Yauk Maik Schuler 《Environmental and molecular mutagenesis》2020,61(1):114-134
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc. 相似文献
12.
13.
Rocco Spagnuolo Alessandro Corea Mariantonietta Blumetti Alessia Giovinazzo Massimiliano Serafino Caterina Pagliuso Raffaele Pagnotta Grazia Curto Cristina Cosco Vincenzo Cosco Rosellina Margherita Mancina Pietro Garieri Anna Papaleo Laura Grande Anna Barilaro Eugenio Garofalo Andrea Bruni Patrizia Doldo 《Journal of advanced nursing》2020,76(11):2993-3002
14.
Danail Hristozov Alex Zabeo Keld Alstrup Jensen Stefania Gottardo Panagiotis Isigonis Laura Maccalman 《Nanotoxicology》2016,10(9):1215-1228
Several tools to facilitate the risk assessment and management of manufactured nanomaterials (MN) have been developed. Most of them require input data on physicochemical properties, toxicity and scenario-specific exposure information. However, such data are yet not readily available, and tools that can handle data gaps in a structured way to ensure transparent risk analysis for industrial and regulatory decision making are needed. This paper proposes such a quantitative risk prioritisation tool, based on a multi-criteria decision analysis algorithm, which combines advanced exposure and dose-response modelling to calculate margins of exposure (MoE) for a number of MN in order to rank their occupational risks. We demonstrated the tool in a number of workplace exposure scenarios (ES) involving the production and handling of nanoscale titanium dioxide, zinc oxide (ZnO), silver and multi-walled carbon nanotubes. The results of this application demonstrated that bag/bin filling, manual un/loading and dumping of large amounts of dry powders led to high emissions, which resulted in high risk associated with these ES. The ZnO MN revealed considerable hazard potential in vivo, which significantly influenced the risk prioritisation results. In order to study how variations in the input data affect our results, we performed probabilistic Monte Carlo sensitivity/uncertainty analysis, which demonstrated that the performance of the proposed model is stable against changes in the exposure and hazard input variables. 相似文献
15.
16.
17.
Marco Maruzzo Umberto Basso Eugenio Borsatti Laura Evangelista Filippo Alongi Orazio Caffo Francesca Maines Sara Galuppo Rocco De Vivo Fable Zustovich Dario Palleschi Andrea Zivi Teodoro Sava Mariella Sorarù Roberto Iacovelli Maurizio Nicodemo Susanne Baier Lucia Fratino Vittorina Zagonel 《Clinical genitourinary cancer》2019,17(1):e187-e194
Background
Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.Patients and Methods
We conducted a multicenter retrospective analysis in the Triveneto region of Italy.Results
One hundred fifty-eight patients received radium 223 in our region. After a median follow-up of 9.5 months, 75 patients died. The median overall survival (OS) was 14.2 months, and the median progression-free survival (PFS) was 6.2 months. Seventy-one (45%) patients achieved progression as best response. Thirty-seven (23%) patients stopped the treatment early because of progression. Eastern Cooperative Oncology Group performance status was prognostic for OS (18.4 vs. 12.3 vs. 7.5 months; 0 vs. 1, P = .0062; 0 vs. 2, P = .0002), whereas previous prostatectomy or docetaxel exposure were not. A neutrophil to lymphocytes ratio ≥ 3 significantly impacted OS (18.1 vs. 9.7 months; P < .001) and slightly impacted PFS (6.6 vs. 5.6 months; P = .05). Patients with a baseline alkaline phosphatase (ALP) value ≥ 220 U/L had worse OS and PFS (24.1 vs. 10.5 months; 7.2 vs. 5.5 months; P < .001). Patients with changes in ALP value achieved better OS (P = .029) and PFS (P = .002). There was no difference according to the line of therapy (0 vs. ≥ 1; P = .490). The main grade 3/4 toxicities were anemia, asthenia, and thrombocytopenia.Conclusion
This large real-world report confirms comparable OS and PFS data when compared with the pivotal study, as well as the predictive role of ALP and neutrophil to lymphocytes ratio. The definition of the optimal position of radium 223 in the treatment of metastatic castration-resistant prostate cancer has still to be defined. 相似文献18.
19.
20.
Martina A. Steurer Jean Costello Rebecca J. Baer Scott P. Oltman Sky K. Feuer Tania Pacheco-Werner Elizabeth Rogers Marta M. Jankowska Jessica Block Molly McCarthy Matthew S. Pantell Christina Chambers Kelli K. Ryckman Laura L. Jelliffe-Pawlowski 《Paediatric and perinatal epidemiology》2020,34(2):130-138